BioStem Technologies has appointed Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee. Ungrodt brings nearly three decades of financial leadership to the role, having spent her career as a senior partner at Ernst & Young advising life sciences companies. She is qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules. As Audit Committee Chair, Ungrodt will oversee the company's financial reporting, internal controls and risk management practices. Her prior experience includes serving as Chair of the Audit Committee for Feeding San Diego, where she provided accounting, budgeting and risk assessment guidance for over a decade. She is also an Advisory Board Member for Life Science Cares. During her tenure at EY, Ungrodt served more than 70 companies across the Life Sciences sector.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that Ungrodt's appointment comes as the company undertakes expansion beyond chronic wound care and plans to raise its profile in the public markets in 2026. Matuszewski emphasized that Ungrodt's twenty-nine years of life sciences accounting experience at Ernst & Young, along with her track record advising more than thirty IPOs and deep regulatory and government expertise, will make a valuable addition to board governance during this pivotal time. Ungrodt replaces former board member Brandon Poe, who accepted the role of BioStem's chief financial officer in August 2025. Poe brings more than 25 years of finance leadership experience across the healthcare and life sciences sectors and served on BioStem's Board of Directors for three years before joining the organization.
Ungrodt expressed excitement about joining BioStem's board at this pivotal time in the company's growth, noting that BioStem stands out as one of the most innovative companies in the MedTech sector. She highlighted the company's strong momentum in the chronic wound market and its recent expansion into acute applications of its industry-leading technologies. Ungrodt stated that these technologies have tremendous potential to improve patient outcomes, and she is honored to take on this important role as the company continues to scale and innovate in this space. BioStem is an emerging leader in placental and umbilical cord-derived tissue products used by clinicians across a variety of medical specialties. Their proprietary allograft portfolio is derived from donated birth tissue, and proprietary processes are designed to optimally preserve the tissue's natural properties.
The company continues to conduct leading-edge research to expand the scientific understanding of placental-derived tissue products and to bring new products to market. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks. These systems and procedures are established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. BioStem's portfolio of quality brands includes its Neox, Clarix, VENDAJE and American Amnion product lines. The latest news and updates relating to the company are available in the company's newsroom at https://tinyurl.com/bsemnewsroom.
